Baidu
map

Blood:Eltrombopag(艾曲波帕)用于ITP成年患者的长期安全性和有效性

2017-10-18 qinqiyun MedSci原创

在2/3期试验中,用Eltrombopag(艾曲波帕)治疗慢性/持续性免疫性特发性血小板减少症(ITP)≤6个月即可增加血小板计数、减少出血。

在2/3期试验中,用Eltrombopag(艾曲波帕)治疗慢性/持续性免疫性特发性血小板减少症(ITP)≤6个月即可增加血小板计数、减少出血。

研究人员进行一非盲的EXTEND研究,评估艾曲波帕用于ITP成年患者的长期安全性和有效性。

共302位患者参与研究,艾曲波帕的中位持续治疗时间是2.37年(2天-8.87年)。第2周时,血小板计数增长的中位值≥50x109/L,并持续贯穿整个治疗期。有259位(85.8%)获得反应(至少一次血小板计数≥50x109/L),133(52%)患者获得持续反应≥25周。

对于血小板计数<15x109/L、已接受过多次治疗和(或)进行过脾切的患者,反应性较低。101位合用ITP治疗药物的患者中有34位至少停用一种药物。1年时,患者出血症状从起始的57%下降至16%。41位(14%)患者因副反应而退出研究:肝胆毒性(7例)、白内障(4例)、头痛(2例)和骨髓纤维变性(2例),其他AEs仅各有1例。在进行治疗的一年里,血栓栓塞(6%)和肝胆毒性(15%)的发生率没有增加。

ENTEND提示长期应用(>6个月)艾曲波帕对于大部分ITP患者可有效维持血小板计数(≥50x109/L)并减少出血。

原始出处:

Raymond S.M.Wong,et al.Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.Blood.October 17,2017. https://doi.org/10.1182/blood-2017-04-748707

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2066637, encodeId=fc48206663e9a, content=<a href='/topic/show?id=1d3d45e090e' target=_blank style='color:#2F92EE;'>#安全性和有效性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45709, encryptionId=1d3d45e090e, topicName=安全性和有效性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Sat Feb 03 08:10:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990270, encodeId=98a719902e054, content=<a href='/topic/show?id=abc896996e1' target=_blank style='color:#2F92EE;'>#长期安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96996, encryptionId=abc896996e1, topicName=长期安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Mon Dec 18 10:10:00 CST 2017, time=2017-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418424, encodeId=dfb11418424db, content=<a href='/topic/show?id=c8f210115bc' target=_blank style='color:#2F92EE;'>#ITP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10115, encryptionId=c8f210115bc, topicName=ITP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2523357226, createdName=whmdzju, createdTime=Fri Oct 20 01:10:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420128, encodeId=39b614201284d, content=<a href='/topic/show?id=7a7286e7153' target=_blank style='color:#2F92EE;'>#艾曲波帕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86771, encryptionId=7a7286e7153, topicName=艾曲波帕)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=776e3562469, createdName=huangdf, createdTime=Fri Oct 20 01:10:00 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2066637, encodeId=fc48206663e9a, content=<a href='/topic/show?id=1d3d45e090e' target=_blank style='color:#2F92EE;'>#安全性和有效性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45709, encryptionId=1d3d45e090e, topicName=安全性和有效性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Sat Feb 03 08:10:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990270, encodeId=98a719902e054, content=<a href='/topic/show?id=abc896996e1' target=_blank style='color:#2F92EE;'>#长期安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96996, encryptionId=abc896996e1, topicName=长期安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Mon Dec 18 10:10:00 CST 2017, time=2017-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418424, encodeId=dfb11418424db, content=<a href='/topic/show?id=c8f210115bc' target=_blank style='color:#2F92EE;'>#ITP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10115, encryptionId=c8f210115bc, topicName=ITP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2523357226, createdName=whmdzju, createdTime=Fri Oct 20 01:10:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420128, encodeId=39b614201284d, content=<a href='/topic/show?id=7a7286e7153' target=_blank style='color:#2F92EE;'>#艾曲波帕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86771, encryptionId=7a7286e7153, topicName=艾曲波帕)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=776e3562469, createdName=huangdf, createdTime=Fri Oct 20 01:10:00 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2066637, encodeId=fc48206663e9a, content=<a href='/topic/show?id=1d3d45e090e' target=_blank style='color:#2F92EE;'>#安全性和有效性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45709, encryptionId=1d3d45e090e, topicName=安全性和有效性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Sat Feb 03 08:10:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990270, encodeId=98a719902e054, content=<a href='/topic/show?id=abc896996e1' target=_blank style='color:#2F92EE;'>#长期安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96996, encryptionId=abc896996e1, topicName=长期安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Mon Dec 18 10:10:00 CST 2017, time=2017-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418424, encodeId=dfb11418424db, content=<a href='/topic/show?id=c8f210115bc' target=_blank style='color:#2F92EE;'>#ITP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10115, encryptionId=c8f210115bc, topicName=ITP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2523357226, createdName=whmdzju, createdTime=Fri Oct 20 01:10:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420128, encodeId=39b614201284d, content=<a href='/topic/show?id=7a7286e7153' target=_blank style='color:#2F92EE;'>#艾曲波帕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86771, encryptionId=7a7286e7153, topicName=艾曲波帕)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=776e3562469, createdName=huangdf, createdTime=Fri Oct 20 01:10:00 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
    2017-10-20 whmdzju
  4. [GetPortalCommentsPageByObjectIdResponse(id=2066637, encodeId=fc48206663e9a, content=<a href='/topic/show?id=1d3d45e090e' target=_blank style='color:#2F92EE;'>#安全性和有效性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45709, encryptionId=1d3d45e090e, topicName=安全性和有效性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Sat Feb 03 08:10:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990270, encodeId=98a719902e054, content=<a href='/topic/show?id=abc896996e1' target=_blank style='color:#2F92EE;'>#长期安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96996, encryptionId=abc896996e1, topicName=长期安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Mon Dec 18 10:10:00 CST 2017, time=2017-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418424, encodeId=dfb11418424db, content=<a href='/topic/show?id=c8f210115bc' target=_blank style='color:#2F92EE;'>#ITP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10115, encryptionId=c8f210115bc, topicName=ITP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2523357226, createdName=whmdzju, createdTime=Fri Oct 20 01:10:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420128, encodeId=39b614201284d, content=<a href='/topic/show?id=7a7286e7153' target=_blank style='color:#2F92EE;'>#艾曲波帕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86771, encryptionId=7a7286e7153, topicName=艾曲波帕)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=776e3562469, createdName=huangdf, createdTime=Fri Oct 20 01:10:00 CST 2017, time=2017-10-20, status=1, ipAttribution=)]

相关资讯

NEJM:添加艾曲波帕的免疫抑制治疗有望成为重症再生障碍性贫血一线治疗方案

对于重症再生障碍性贫血患者,加入艾曲波帕的免疫抑制治疗可显着提高患者血液学反应率

NEJM:艾曲波帕可改善难治性再生障碍性贫血

       《新英格兰医学杂志》(N Engl J Med)7月5日发表的一项研究表明在一些难治性重度再生障碍性贫血患者中,用艾曲波帕治疗与多系临床缓解相关。        免疫抑制疗法或同种异体移植可有效地治疗重度再生障碍性贫血(以免疫介导的骨髓发育不全和全血细胞减少为特征)。1/3

Lacnet:艾曲波帕对慢性免疫性血小板减少症儿童患者是有效的

对患有慢性免疫性血小板减少症的成年患者,促血小板生成素受体激动剂艾曲波帕被证明是安全、可耐受、且有效的。研究者进行了一项研究(PETIT2),探究该药物对慢性免疫性血小板减少症的儿童患者的安全性和有效性。PETIT2是在12个国家38个中心进行的随机、多中心、安慰剂对照试验。参与者为1-17岁慢性免疫性血小板减少症患者,其血小板计数低于30 × 109 /L,将其随机分为艾曲波帕组和对照组。研究者

FDA扩大了艾曲波帕片在ITP中的使用年龄

美国食品和药物管理局(FDA)近期宣布,它已经扩大了艾曲波帕片(eltrombopag (Promacta, Novartis))在一种罕件的血液紊乱病--慢性免疫性血小板减少性紫癜(ITP)中的使用年龄,包括1岁的的患儿也能使用该药。这则消息紧接着FDA在6月份的决定,要扩大该药在6岁及以上患儿的使用指标。通常,ITP患者血小板水平会异常的低。FDA在发布这则消息时说道:“人

Baidu
map
Baidu
map
Baidu
map